Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

06/21/2013 | 05:03am US/Eastern

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
Latest news
Date Title
<1m ago US Crude Exports And Re-Exports Continue To Rise; Some Volumes Sent To Europe And Asia – Analysis
<1m ago SYNAPTICS : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
<1m ago FIVE PRIME THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
<1m ago CHUBB : Reports 3rd Quarter 2014 Results
<1m agoDJMARKET SNAPSHOT : Dow Rises 217 Points As U.S. Stocks Notch Solid Gains
<1m ago ENVISION HEALTHCARE : to Release Third Quarter Operating Results Wednesday, November 5, 2014 and Participate in Upcoming Investor Conference
1m ago AMAZON : posts 3Q loss, results miss Wall Street forecasts
1m ago PFIZER : approves $11B stock repurchase plan
1m ago AMERICAN REALTY CAPITAL PROPERTIES : Other Events (form 8-K)
1m ago NPS PHARMACEUTICALS : PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015
Latest news
Advertisement
Hot News 
OIM : 16 october 2014 - PAYMENT OF DIVIDENDS SUSPENDED
CABELAS : Cabela’s® Announces Plans for Two New Stores
JAKKS PACIFIC : reg; Reports Improved Third Quarter Results for 2014
INFINERA : beats Street 3Q forecasts
FOXTONS : Downgrades Full-Year Earnings Guidance On Poor Third Quarter
Most Read News
1d ago ATMEL : Patent Issued for Apparatus and Method for Increasing the Quantity of Discrete Electronic Components in an Integrated Circuit Package
1d ago EXELON : ICC Approves ComEd’s Grand Prairie Gateway Project
1d ago TERADYNE : beats Street 3Q forecasts
4h ago Tesco accounting black hole deepens, chairman to step down
1h ago Unilever promises more cheap goods, cost cuts to tackle slowdown
Most recommended articles
2m agoDJMARKET SNAPSHOT : Dow Rises 217 Points As U.S. Stocks Notch Solid Gains
3m ago APPLE : GT Advanced shareholders see value in stock despite bankruptcy
3m agoDJCURRENCIES : Dollar Hits Two-and-a-half Week High Against Yen
9m ago AMAZON : holiday quarter sales forecasts disappoint, shares dive
11m ago Fed lays out scenarios for 2015 bank stress tests
Dynamic quotes  
ON
| OFF